Compare WS & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WS | NVAX |
|---|---|---|
| Founded | 1955 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2023 | 1996 |
| Metric | WS | NVAX |
|---|---|---|
| Price | $39.72 | $11.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.22 |
| AVG Volume (30 Days) | 437.3K | ★ 8.1M |
| Earning Date | 10-06-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,443,800,000.00 | $1,123,479,000.00 |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $0.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 11.33 | ★ 64.69 |
| 52 Week Low | $27.22 | $6.20 |
| 52 Week High | $49.17 | $13.39 |
| Indicator | WS | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 61.42 | 50.30 |
| Support Level | $38.01 | $7.93 |
| Resistance Level | $39.42 | $11.73 |
| Average True Range (ATR) | 1.92 | 1.13 |
| MACD | 0.34 | 0.01 |
| Stochastic Oscillator | 80.29 | 28.62 |
Worthington Steel Inc is a value-added metals processors with the ability to provide a diversified products and services that span a variety of end markets. It is a value-added processor of carbon flat-rolled steel and a producer of laser welded solutions and electrical steel laminations. It is one of the independent intermediate processors of carbon flat-rolled steel in the U.S. It occupy a niche in the steel industry by focusing on products requiring exact specifications. The company has one operating and reportable segment. It has presence in United States, Canada, Mexico, and Rest of world. The company has majority of sales from United States.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.